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RecombinasesDespite phenomenal advances in AIDS therapy transforming the disease into a chronic illness for most
patients, a routine cure for HIV infections remains a distant goal. However, a recent example of HIV erad-
ication in a patient who had received CCR5-negative bone marrow cells after full-body irradiation has
fuelled new hopes for a cure for AIDS. Here, we review new HIV treatment strategies that use sophisti-
cated genome engineering to target HIV infections. These approaches offer new ways to tackle the infec-
tion, and alone or in conjunction with already established treatments, promise to transform HIV into a
curable disease.
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Combination antiretroviral therapy (ART), introduced into clin-
ical practice in the mid-1990s, has profoundly reduced HIV-associ-
ated morbidity and mortality, changing a lethal disease into a
chronic illness (Palella et al., 1998; Thompson et al., 2010).
Although ART can suppress viral loads below the detection limit
of standard clinical assays (<50 HIV-1 RNA copies/mL), it cannot
eliminate HIV. This is due on the fact that ART targets virus entry
or the viral enzymes, but not the integrated provirus. Therefore,ART requires lifelong treatment, potentially leading to problems
of cost (Chen et al., 2006; Schackman et al., 2006), adherence
(Mannheimer et al., 2002; Paterson et al., 2000), drug resistance
(Little et al., 2002; Richman, 2006) and toxicity (Dybul et al.,
2002). Particularly, long-term treatment frequently results in sec-
ondary complications, such as diabetes, hyperlipidemia, cardiovas-
cular disease, osteoporosis, and chronic kidney disease (Calmy
et al., 2009; Deeks and Phillips, 2009).
More importantly, patients successfully treated with ART for
several years still do not fully recover their immune responses,
and show increased levels of immune activation along with its
harmful effects (Ostrowski, 2010; Plana et al., 1998). Consequently,
low-level viral replication may persist along with an established
pool of latently infected cells (Finzi et al., 1997, 1999; Palmer
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quickly rebound, even in patients who have suppressed plasma
viremia to levels below detection limits for many years (Davey
et al., 1999). Therefore, developing novel therapeutic strategies
aiming to cure HIV infection must address the pool of cells that
harbor the latent HIV reservoir (Chun and Fauci, 2012; Deeks
et al., 2012; Richman et al., 2009).
In principle, two qualitatively different types of cure have been
deﬁned (Dieffenbach and Fauci, 2011; Lafeuillade, 2011; Lewin
et al., 2011). In a ‘‘functional cure’’ the patient’s immune defense
fully controls HIV in the absence of ART. However, proviral DNA
can still be found in the body. In contrast, a ‘‘sterilizing cure’’ erad-
icates HIV and no viral genes remain in the infected host. Clearly, a
functional cure may be easier to achieve, but a sterilizing cure is
considered to be the holy grail of HIV therapy.2. Purging the reservoir
The long-lived resting cells that contain HIV reservoirs reside
primarily in tissues, in other words sanctuary sites that may not
be easily accessible (Lafeuillade, 2012; Palmer et al., 2011; Smith
et al., 2012). The proviral DNA (i.e. the integrated replication-com-
petent HIV genome) in these cells is transcriptionally silenced,
mainly due to epigenetic modiﬁcations of the viral long terminal
repeat (LTR) promoter region (Coiras et al., 2009; Geeraert et al.,
2008; Richman et al., 2009). Hence the viral antigens are not ex-
pressed, and in consequence, these HIV-infected host cells evade
immune surveillance. Importantly, the existence of these viral res-
ervoirs is believed to be the main hurdle to quantitatively clearing
the virus from an infected organism. So far, the main and also best
characterized reservoir comprises latently infected resting mem-
ory CD4+ T cells containing replication-competent but dormant
proviral DNA (for recent reviews on HIV reservoirs see Chun and
Fauci, 2012; Lafeuillade, 2012; Margolis, 2011a; Palmer et al.,
2011; Smith et al., 2012).
An important mechanism for maintaining transcriptional qui-
escence of the provirus, and hence viral latency, relies on cellu-
lar chromatin remodeling enzymes, in particular histone
deacetylases (HDACs) (Hakre et al., 2011; Margolis, 2011b).
Therefore, a main strategy currently being investigated for elim-
inating HIV reservoirs is based on pharmacologically inhibiting
HDACs, thereby speciﬁcally activating latent proviral genomes
in resting CD4+ T cells. Upon HIV antigen expression, it is ex-
pected that these cells will be eliminated through either direct
cytophatic viral effects or immune responses of the host (e.g.
cytotoxic T cells; CTL).
Indeed, the HDAC inhibitor (HDACi) suberoylanilide hydroxa-
mic acid (SAHA; Vorinostat), an FDA-approved drug for treating
cutaneous T cell lymphoma, did speciﬁcally reactivate HIV from la-
tency in chronically infected cell lines and primary cells (Archin
et al., 2009; Contreras et al., 2009; Edelstein et al., 2009). More re-
cently, SAHA has been administered to ART-treated HIV-positive
patients with fully suppressed viremia (Archin et al., 2012). In a
majority of these patients, SAHA not only affected cellular acetyla-
tion but also upregulated HIV-speciﬁc RNA expression in their rest-
ing CD4+ T cells. Clearly, this increase in cell-associated HIV RNA
does not necessarily imply that the respective cells could produce
viral progenies. Nevertheless, reactivation of latent HIV expression
by applying chromatin remodeling drugs, such as HDAC inhibitors,
may be an essential mechanism to trigger HIV eradication in vivo
(Durand et al., 2012). Doubtless, such a strategy will be applied
in combination with ART to avoid de novo infection during activa-
tion of the latent virus reservoir.
As mentioned above, HDACi-induced (i.e. SAHA-induced) acti-
vation of latent HIV was generally expected to result in cell deathdue to either cytopathic viral effects or CTL action. Unfortunately,
in another recent study it was shown that neither is the case, even
when autologous CTLs from ART-treated patients were present
(Shan et al., 2012). Instead, after virus reactivation CD4+ T cells
were only killed by CTLs when the cytotoxic T cells were pre-stim-
ulated with HIV-1 Gag peptides.
These data demonstrate that HDAC inhibitor-induced activa-
tion of latent HIV will presumably not sufﬁce to eradicate the
long-term viral reservoirs by clearing the pool of latently infected
cells. It has therefore been suggested that some form of therapeu-
tic vaccination and/or additional interventions may be required
for successful purging/eradication attempts (Archin et al., 2012;
Shan et al., 2012). These may include gene therapy strategies
(Kiem et al., 2012; van Lunzen et al., 2011). This notion is also
supported by a more recent study in which various HDAC inhib-
itors (HDACis), including SAHA, were analyzed with respect to
HIV production (Blazkova et al., 2012). It was demonstrated that,
in aviremic individuals, HDACis only stimulate HIV expression in
a small fraction of latently infected resting CD4+ T cells and may
therefore not be able at eliminating these viral reservoirs. The
authors therefore suggested that alternative therapeutic strate-
gies that incorporate HIV-speciﬁc targeting and/or immune acti-
vation approaches will be necessary to clear latent HIV
(Blazkova et al., 2012).3. A singular case of an HIV cure
In 2009, publication of the so-called ‘‘Berlin patient’’ case report
revived the notion that a cure for HIV infection might be feasible
(Hütter et al., 2009). This HIV-infected patient suffered from acute
myeloid leukemia (AML). After failure of chemotherapy, the pa-
tient received hematopoietic stem cells (HSCs) from an HLA-iden-
tical donor selected for CCR5D32 homozygosity. This very rare
mutation in Caucasians (1% occurrence) inactivates the CCR5
gene which encodes a critical HIV co-receptor (Liu et al., 1996).
The patient received fully ablative and potentially lethal condition-
ing regimes in combination with two successive HSC transplanta-
tions. This procedure led to a complete remission of the AML
(Hütter et al., 2009). Importantly, however, prior to transplantation
the patient discontinued ART and for more than ﬁve years now
shows no signs of HIV infection (Allers et al., 2011; Hütter and
Thiel, 2011).
This is of particular interest, since before treatment a minor
population (2.9%) of CCR5-independent virus variants (i.e.
CXCR4-tropic or dual-tropic viruses) was also detected in the pa-
tient. Why these viruses did not rebound after ceasing ART, partic-
ularly in light of the fact that a high proportion of potential target
cells (e.g. activated memory CD4+ T cells) were recovered after
transplantation, is unclear at the moment (Hütter and Ganepola,
2011). Nonetheless, it is conceivable that the harsh myeoablative
conditioning of the patient or other immune reactions may have
been responsible for this fortunate outcome.
Obviously, this approach cannot be applied to larger HIV patient
cohorts for various reasons. For example, HLA-matched CCR5D32
homozygous donors are extremely rare, which in fact has so far
prevented the treatment of another patient (Hütter and Thiel,
2011). Also equally prohibiting is the relatively high rate of mortal-
ity (26%) connected with the procedure of allogeneic HSC trans-
plantation (Gooley et al., 2010). Nevertheless, this unique case of
the ‘‘Berlin patient’’ obviously jump-started the ﬁeld of HIV eradi-
cation and latency research by demonstrating that an HIV cure is
possible under certain, although extremely rare conditions. This
case may also suggest that the genetic alteration of host cells, ren-
dering them resistant to HIV, may be an important component of
future eradication strategies.
Fig. 1. Genetic therapies against HIV. Either the patient’s peripheral CD4+ T cells or the patient’s CD34+ HSPCs are usually genetically modiﬁed ex vivo using gene transfer
vectors. Autologous re-infusion of enriched modiﬁed T cells is expected to result in antiviral, although transient, effects. This technical approach will probably ﬁnd its major
application in the context of a functional cure. Bone marrow-derived CD34+ stem cells are commonly collected upon G-CSF mobilization by leukapheresis. Following genetic
ex vivomanipulation, autologous transplantation and engraftment of the patient’s bone marrow with these cells is expected to perpetually repopulate the patient’s peripheral
blood and lymphoid tissues with HIV-1 resistant cells. Therefore, stem cell-based gene therapies will most likely be applied in the context of a sterilizing cure. Clearly, both
approaches may also be combined, either with each other, or for example, with vaccination strategies or novel pharmacological approaches.
F. Buchholz, J. Hauber / Antiviral Research 97 (2013) 211–217 2134. CCR5 inactivation by gene therapy
In principle, genetic therapies against HIV either modify the pa-
tient’s peripheral blood CD4+ T cells or patient-derived CD34+
hematopoietic stem and progenitor cells (HSPCs) (Kiem et al.,
2012; Rossi et al., 2007; Scherer and Rossi, 2011) (Fig. 1). T cell
modiﬁcation most likely results in transient effects, and may there-
fore be the strategy applied in a functional cure. In contrast, the ge-
netic alteration of HSPCs allows the perpetual repopulation of the
patient’s hematopoietic system with genetically modiﬁed cells of
all lineages, including the most relevant HIV host cells (e.g. lym-
phocytes, and monocytes). These HIV-resistant cells are expected
to be selected in vivo (Baltimore, 1988), an assumption that clearly
remains to be proven in a clinical setting. In theory, the patient’s
immune system should be functionally reconstituted, which is
considered to be an important precondition for elimination of virus
reservoirs (i.e. virus eradication). Therefore, stem cell gene therapy
will most likely be the method of choice when a sterilizing cure is
pursued.
A promising gene therapy approach that somehow mimics the
case report of the ‘‘Berlin patient’’ is disrupting the CCR5 gene by
expressing an engineered zinc ﬁnger nuclease (ZFN). ZFNs are
modular, designer DNA editing enzymes that comprise an array
of zinc ﬁnger domains (commonly three to six) each recognizing
a speciﬁc DNA triplet (Porteus and Carroll, 2005; Schiffer et al.,
2012; Urnov et al., 2010). This substrate binding domain is fused
to an unspeciﬁc nuclease domain commonly derived from the
restriction endonuclease FokI. Since ZFNs act as dimers, appropri-
ate positioning of two ZFN monomers, binding to the opposite
strands on either site of a spacer region, results in DNA double-
strand breaks (DSBs) at the spacer region (Fig. 2). DSBs are then fre-
quently ‘‘repaired’’ by the cell’s error-prone, non-homologous end
joining (NHEJ) pathway, a process that often results in localized se-
quence deletions or the addition of unrelated bases (Naldini, 2011;Porteus and Carroll, 2005). Thus, speciﬁcally directing ZFNs to the
CCR5 locus can disrupt the cellular CCR5 receptor, conferring resis-
tance to de novo infection by CCR5-tropic HIV-1.
In experiments, adenovirus (Ad) vector-mediated transient
expression of CCR5-speciﬁc ZFNs speciﬁcally disrupted 50% of
CCR5 alleles in a pool of primary human CD4+ T cells; furthermore,
CCR5-tropic HIV-1 infected mice engrafted with these transduced
T cells displayed lower viral loads than animals engrafted with
ZFN-untreated CD4+ T cells (Perez et al., 2008). A subsequent study
extended this T cell-based strategy to mice that were engrafted
with human CD34+ HSPCs. Prior to transplantation, transfection
of the HSPCs with ZFN-expressing plasmid vectors resulted in
CCR5 disruption (5–7% of CCR5/ cells in the transfected popula-
tion) and in vivo selection of ZFN-modiﬁed cells in the hematopoi-
etic multi-lineage progeny. Again, analysis of viral loads and CD4+
T cell counts demonstrated that ZFN-treated animals controlled
HIV-1 replication more efﬁciently than mice that received ZFN
non-transfected HSPCs (Holt et al., 2010).
Taken together these studies suggest that ZFN-mediated inacti-
vation of CCR5, by modifying either peripheral CD4+ T cells or
CD34+ HSPCs, is a highly promising approach to conferring resis-
tance to HIV-1 in vivo. Evidently, this approach closely resembles
the treatment strategy applied in the case of the ‘‘Berlin patient’’
to facilitate virus eradication (Deeks and McCune, 2010; Durand
et al., 2012; Schiffer et al., 2012). It should be noted that a clinical
trial is currently underway to analyze the potential of CCR5-spe-
ciﬁc ZFN in the context of a functional cure. In this trial peripheral
CD4+ T cells are isolated from HIV-infected patients, genetically
modiﬁed ex vivo using an Ad-vector, and returned by autologous
re-infusion (Tebas et al., 2011).
As outlined, ZFNs are valuable tools for site-directed genome
engineering (Urnov et al., 2010), particularly for disrupting the
CCR5 gene as part of clinical HIV eradication studies. However,
various undesired toxic effects may be connected with this
Fig. 2. Mode of action of CCR5-speciﬁc ZFNs. A dimer of in vitro engineered ZFNs
speciﬁcally recognizes the CCR5 locus via its zinc ﬁnger domains. Subsequently, the
unspeciﬁc ZFN nuclease domains (scissors) introduce DNA double-strand breaks
(DSBs) that are ‘‘repaired’’ by the cellular error-prone non-homologous end-joining
(NHEJ) pathway. This process frequently results in disruption of the CCR5 locus
(asterisk), rendering the cell resistant to infection with CCR5-tropic HIV.
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share some degree of homology with the intended target sequence.
For example, it has already been established that CCR5-speciﬁcZFNs also target the CCR2 locus to a signiﬁcant extent (Perez
et al., 2008). Two recent independent studies reported CCR5-spe-
ciﬁc ZFN cleavage of additional (>13) human gene sequences (Gab-
riel et al., 2011; Pattanayak et al., 2011). Clearly, these off-target
effects may be particularly troubling when stem cell (HSPC)-based
gene therapies using CCR5-speciﬁc ZFNs are considered for clinical
use.
The problem of genotoxicity due to unspeciﬁc cleavage may be
avoided by using transcription activator-like effector nucleases
(TALENs). Like ZFNs, TALENs are modular, structured designer nuc-
leases that commonly combine an extended DNA targeting motif
containing a variable number of tandem 34 amino acid repeats that
each recognize a single nucleotide, plus the FokI endonuclease do-
main (Bogdanove and Voytas, 2011; Li et al., 2011). Since TALENs
are engineered to recognize longer target sequences, binding spec-
iﬁcity is greatly improved, thereby minimizing off-target effects.
Supporting this notion, a CCR5-speciﬁc TALEN recently compared
side-by-side with the corresponding ZFN demonstrated similar
gene disruption activities, but clearly reduced nuclease-associated
cytotoxicities (Mussolino et al., 2011).
Another drawback of ZFN- as well as TALEN-mediated CCR5
knockout may derive from the fact that the cleavage (and hence
disruption) of the CCR5 locus results in DSBs that activate the cel-
lular error-prone NHEJ pathway. Unfortunately, DSBs represent
one of the most dangerous lesions for a cell, and can potentially re-
sult in oncogenic catastrophe (Hiom, 2010; Porteus and Carroll,
2005).
Finally, it should also be noted that disrupting the CCR5 mole-
cule is not an effective strategy to block infection or outgrowth
of CCR5-independent viruses, such as CXCR4-tropic or dual-tropic
HIV-1.5. Targeting the HIV provirus
Speciﬁc endonucleases, such as ZFNs, TALENs, or homing endo-
nucleases (HEs) (Stoddard, 2011), may also be used to directly tar-
get integrated HIV proviral DNA. Here, a DSB is induced in an
essential region within the provirus, again followed by host cell-
mediated error-prone NHEJ. Indeed, it has been recently demon-
strated that a lentiviral vector-derived artiﬁcial GFP reporter con-
struct, that was engineered to contain a single HE recognition
site, was inactivated by HE expression (Aubert et al., 2011). So
far, however, no HE being capable of recognizing a native HIV tar-
get sequence has been reported, which would be prerequisite to an
application in future HIV eradication strategies.
Another approach that likely depends on gene therapy directly
targets the integrated proviral DNA using a tailored long terminal
repeat (LTR)-speciﬁc recombinase (Tre-recombinase) (Buchholz
and Hauber, 2011; Sarkar et al., 2007). The Tre enzyme speciﬁcally
recognizes and recombines a 34 bp sequence, called loxLTR that is
located in the proviral LTRs. This results in excising the intermedi-
ary sequences from the genome of the host cell, including all viral
genes (Sarkar et al., 2007). A single LTR remains at the chromo-
somal integration site, while the circular integration-deﬁcient exci-
sion product is eventually degraded by cellular nucleases (Fig. 3).
Thus, Tre-recombinase can reverse an already established infection
by removing integrated HIV-1 from infected host cells. Fortunately,
this process is independent of virus tropism, i.e. CCR5- and CXCR4-
tropic viruses are removed equally well.
Recapitulating the gene therapy scenarios discussed above, a
Tre-based eradication strategy may include lentiviral vector
(LV)-mediated Tre delivery into either the patient’s peripheral
CD4+ T cells or CD34+ HSPCs. Moreover, the fact that Tre is only re-
quired in HIV-1 infected cells permits conditional expression of
Tre either by placing the tre gene under the control of a
Fig. 3. Mode of action of LTR-speciﬁc Tre-recombinase. Tre-recombinase is a Cre-
derived enzyme obtained in vitro by molecular evolution. Tre acts error-free as a
tetramer recognizing and recombining a sequence located in the proviral LTRs
(triangle). This process results in excision of the proviral genome from the host cell
chromosome. The excision product is degraded and a single LTR remains at the
integration site.
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(Lachmann et al., 2012), or by employing a promoter responsive
to the HIV-1 Tat transcriptional trans-activator. Particularly, thelatter strategy is expected to be combined with and to beneﬁt from
the concomitant administration of viral reservoir purging drugs
(e.g. SAHA). Clearly, such a Tre expression strategy could minimize
potential transgene-related (i.e. Tre-related) toxicities. A recent
analysis of Tat-dependent Tre expression in HIV-1-infected
humanized mice indeed demonstrated pronounced antiviral ef-
fects of Tre-recombinase in the absence of cellular toxicities, irre-
spective of whether the animals were engrafted with either Tre
vector-transduced human CD4+ T cells or Tre-transduced human
CD34+ HSPCs (Buchholz & Hauber, unpublished). These studies
suggest that Tre-recombinase may indeed become an important
tool in therapies that aim to overcome the obstacle of virus
clearance.
Tre is a site-speciﬁc recombinase derived from Cre recombinase
engineered in vitro by molecular evolution to act on a native HIV-1
target site (Sarkar et al., 2007). Cre recombinase is widely used in
mouse genetics and has been intensively studied (Glaser et al.,
2005; Van Duyne, 2001). Particularly in clinical applications, it
seems to be advantageous that such recombinases, including Tre,
neither produce DSBs nor require additional host factors such as
the NHEJ pathway. As a result, the recombination process is very
precise and usually error-free (Glaser et al., 2005; Van Duyne,
2001).
Nevertheless, prior to clinical application various potential
problems connected with the Tre technology have to be resolved.
For example, current Tre-recombinase was raised against a pri-
mary HIV-1 subtype A isolate (Blackard et al., 1999). It is therefore
expected that for broader applications a Tre-recombinase also rec-
ognizing a majority of HIV-1 subtypes must be developed. Like-
wise, Tre treatment may select for outgrowth of resistant viruses
resulting from target (loxLTR) site mutation. Both aspects may be
addressed by identifying Tre target sequences that are highly con-
served in the LTRs of a vast majority of HIV-1 isolates. The recent
development of a novel ‘‘locus of recombination site’’ search tool
and the description of a collection of conserved sequences covering
a maximum of HIV-1 variants will certainly be helpful in achieving
this goal (McIntyre et al., 2009; Surendranath et al., 2010).
Even if it turns out that a sterilizing cure cannot be achieved, Tre
technology may also be applicable in a functional cure for ex vivo
treatment of PBMCs. For this, Tre-recombinase could be expressed
as a fusion with a cell-penetrating protein transduction domain
(PTD) or membrane translocation motif (TLM) (Fonseca et al.,
2009). As reported recently, directly adding recombinant PTD/
TLM-Tre fusion protein to a productively infected T cell culture re-
sulted in efﬁcient protein translocation and excision of the full-
length HIV-1 proviral DNAs from their chromosomal integration
sites (Mariyanna et al., 2012).6. Conclusions and future perspectives
The growing recognition that a cure for HIV infection is not only
needed but also feasible is based on signiﬁcant advances in basic,
translational, and clinical research (Deeks et al., 2012). The remark-
able case of the ‘‘Berlin patient’’ particularly revived the idea of
gene therapy strategies to eradicate HIV (Kiem et al., 2012; van
Lunzen et al., 2011). Indeed, expression of in vitro engineered en-
zymes disrupting the CCR5 surface receptor and/or excising the
HIV-1 proviral DNA may become critical components of future
therapies aiming at virus eradication.
It is generally expected that, if achievable at all, no single ap-
proach will lead to a sterilizing cure. Rather, a clever combination
of drug treatments, therapeutic vaccination strategies, possibly in
combination with antiviral gene therapy, likely offers the highest
hope for defeating HIV. Gene therapies expressing engineered en-
zymes generally modify cells of the hematolymphoid system, with
216 F. Buchholz, J. Hauber / Antiviral Research 97 (2013) 211–217the goal of conferring HIV resistance. In turn, this should contrib-
ute to improving the patient’s immune responses, enabling the
clearance of latently infected cells. Obviously, direct targeting of
these resting cells with any antiviral vector will not be possible
in the very near future. However, a Tre-based approach in combi-
nation with chromatin remodeling drugs speciﬁcally activating
the HIV LTR promoter of latent proviruses, as well as the Tre-
expressing vector, may be conceivable as part of a future strategy
to eradicate latent infection. In more general terms it is envisaged
that stem cell-based gene therapies, employing designer enzymes,
will provide the groundwork for adding various additional antiviral
strategies to achieve a cure for HIV infection.
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